A second phase 1/2 study of KP1237 in treatment for Darzalex®-relapsed/refractory multiple myeloma patients
Latest Information Update: 09 Feb 2022
At a glance
- Drugs KP 1237 (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions; Therapeutic Use
- 08 Sep 2020 According to a Kleo Pharmaceuticals media release, this trial is expected to begin in 4Q2020.
- 31 Jul 2020 New trial record
- 29 Jul 2020 According to a Kleo Pharmaceuticals media release, the company anticipates to initiate this study in 2020